MAM
BBIO icon

Marquette Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Marquette Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$596 Sell
8
-19
-70% -$1.33K ﹤0.01% 791
2026
Q1 		$2.01K Buy
27
+19
+238% +$1.38K ﹤0.01% 543
2025
Q4 		$612 Buy
+8
New +$525 ﹤0.01% 607

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Marquette Asset Management's BBIO Position: Q2 2026 in Review

Marquette Asset Management reduced its BridgeBio Pharma (BBIO) stake by 70% in Q2 2026, selling an estimated $1.33K and leaving 8 shares worth $596. The position accounts for ﹤0.01% of the portfolio, ranked #791.

Marquette Asset Management first reported a position in BBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.01K in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Marquette Asset Management held 8 shares of BridgeBio Pharma worth $596 as of Q2 2026.
  • Marquette Asset Management sold 19 BridgeBio Pharma shares in Q2 2026, an estimated $1.33K.
  • BridgeBio Pharma made up ﹤0.01% of Marquette Asset Management's portfolio in Q2 2026, its #791 holding.
  • Marquette Asset Management first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 3 quarters since.
  • Marquette Asset Management's BridgeBio Pharma position peaked at $2.01K in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Marquette Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.